What’s Next for Affymax, Inc. (AFFY)?
From Insider Monkey - Free Hedge Fund and Insider Trading Data
January 22, 2013 - 8:02pm
Affymax, Inc. (NASDAQ:AFFY) received its first Food and Drug Administration approval last spring with Omontys for anemia in dialysis patients. The drug enters a war against Amgen, Inc. (NASDAQ:AMGN)‘s Epogen, which has held a near monopoly for over 20 years. As its lone product enters the market, what’s next for Affymax? Let’s make a deal [...]
Continue reading this article »
Share This Article: